GSK plc (LSE/NYSE: GSK) today announced that the European Medicines ... The current presentation of the vaccine consists of a lyophilised (powder) antigen and a liquid adjuvant, which healthcare ...

Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for ...

The First in China! BLA Submitted for Luzhu Biotech's Recombinant Herpes Zoster Vaccine Expected to Be Launched in 2026 HONG KONG ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in ... Gammagard Liquid/Kiovig, Hyqvia, Cuvitru ...

Wellnex Life Ltd (ASX:WNX) is supplying the liquid softgel painkillers being sold by $60 billion UK giant Haleon under its ...

Dr Okafo has more than 22 years’ experience in the pharmaceutical industry in legacy companies of GSK (SK&F and SB ... volumetric and thermal flowmeters for assessing and validating liquid ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...